The estimated Net Worth of Mitchel Sayare is at least $3.47 Million dollars as of 24 September 2020. Mitchel Sayare owns over 25,275 units of Altimmune Inc stock worth over $189,023 and over the last 21 years he sold ALT stock worth over $3,214,600. In addition, he makes $65,000 as Chairman of the Board at Altimmune Inc.
Sign up
Mitchel Sayare ALT stock SEC Form 4 insiders trading
Mitchel has made over 24 trades of the Altimmune Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 25,275 units of ALT stock worth $181,222 on 24 September 2020.
The largest trade he's ever made was selling 200,000 units of Altimmune Inc stock on 5 November 2009 worth over $1,500,000. On average, Mitchel trades about 27,014 units every 149 days since 2003. As of 24 September 2020 he still owns at least 26,363 units of Altimmune Inc stock.
You can see the complete history of Mitchel Sayare stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mitchel Sayare biography
Dr. Mitchel B. Sayare Ph.D. serves as Chairman of the Board of the Company. Dr. Sayare served as the Chairman of the Board of public company ImmunoGen, Inc. (a position he had held since 1989). In addition, he served as ImmunoGen’s Chief Executive Officer from 1986 to December 31, 2009, and as its President from 1986 to 1992, and from 1994 to July 2008. Prior to joining ImmunoGen, he served as Vice President of Development of Xenogen from 1982 to 1985. Prior to that he was Assistant Professor of Biophysics and Biochemistry at the University of Connecticut. Dr. Sayare earned a Ph.D. in biochemistry from Temple University School of Medicine. Dr. Sayare is a director of Boston IVF, Inc. and Advanced Aesthetic Technologies, Inc., both privately-held companies. Dr. Sayare was chosen to serve as a director of Altimmune because of his substantial experience as a board member and executive officer of biotechnology companies.
What is the salary of Mitchel Sayare?
As the Chairman of the Board of Altimmune Inc, the total compensation of Mitchel Sayare at Altimmune Inc is $65,000. There are 7 executives at Altimmune Inc getting paid more, with Dr. Vipin K. Garg Ph.D. having the highest compensation of $897,696.
How old is Mitchel Sayare?
Mitchel Sayare is 72, he's been the Chairman of the Board of Altimmune Inc since 2018. There are 1 older and 13 younger executives at Altimmune Inc. The oldest executive at Altimmune Inc is David Drutz, 81, who is the Independent Director.
What's Mitchel Sayare's mailing address?
Mitchel's mailing address filed with the SEC is C/O ALTIMMUNE, INC.,, 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.
Insiders trading at Altimmune Inc
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners..., and Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
What does Altimmune Inc do?
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
What does Altimmune Inc's logo look like?
Complete history of Mitchel Sayare stock trades at Altimmune Inc and Immunogen
Altimmune Inc executives and stock owners
Altimmune Inc executives and other stock owners filed with the SEC include:
-
Dr. Vipin K. Garg Ph.D.,
Pres, CEO & Director -
William Brown,
Chief Financial Officer, Principal Accounting Officer -
Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF,
Chief Medical Officer -
Vipin Garg,
President, Chief Executive Officer, Director -
Dr. M. Scot Roberts,
Chief Scientific Officer -
John Gill,
Independent Director -
M. Scott Harris,
Chief Medical Officer -
Mitchel Sayare,
Chairman of the Board -
Ashley Robinson,
IR Contact Officer -
Klaus Schafer,
Independent Director -
Wayne Pisano,
Independent Director -
Philip Hodges,
Independent Director -
David Drutz,
Independent Director -
Diane Jorkasky,
Director -
M. Scot Roberts,
Chief Scientific Officer -
José Ochoa,
Chief Bus. Officer -
Bertrand Georges Ph.D.,
Chief Technology Officer -
Richard I. Eisenstadt M.B.A.,
CFO and Principal Financial & Accounting Officer -
Sybil Tasker,
Chief Medical Officer -
Philip Hodges,
Director -
Derace L Schaffer,
Director -
Capital S.A.S. Truffle,
10% owner -
Bioventures Ltd Novartis Ag...,
-
William Enright,
President and CEO -
Elizabeth Czerepak,
CFO and EVP Corp. Development -
Healthcare Capital Partners...,
-
Pharmaceutical Holdings Llc...,
10% owner -
Richard I Eisenstadt,
Chief Financial Officer -
Raymond M Jordt,
Chief Business Officer -
Catherine A. Sohn,
Director -
Andrew Shutterly,
Acting Chief Financial Officer